Vol.

No.

February 07, 2020Feb 07, 2020

DOWNLOAD THE PDF

Cover Story

Are drugs really driving the latest drop in lung cancer mortality?

Looks like treatment is playing a role, experts say

By Matthew Bin Han Ong

On Jan. 8, the American Cancer Society published its annual estimates of new cancer cases and deaths, declaring that the latest data—from 2016 to 2017—show the “largest ever single-year drop in overall cancer mortality of 2.2%.”

Conversation with The Cancer Letter

ACS's Siegel: Large drop in lung cancer mortality likely driven by treatment, not just drugs

By Matthew Bin Han Ong

Conversation with The Cancer Letter

NCI's Penberthy: We may be seeing some impact of treatment in lung cancer mortality, but we need more data

By Matthew Bin Han Ong

American Cancer Society CEO Gary Reedy cedes day-to-day operations to chief operating officer

By Paul Goldberg

In Brief

Satish Gopal named director of the NCI Center for Global Health

Livestrong updates its mission—and unveils new logo

David Ann, Yilun Liu named deans at City of Hope graduate program

Krystyna Kowalczyk named CEO of Moffitt's immunotherapy CRO

Brandi Felser named executive director of Sarcoma Foundation of America

LUNGevity releases state-by-state Lung Cancer Scorecard

UPenn receives ACGT grant for CAR T-cell clinical trial in prostate cancer

Clinical Roundup

Survey finds gaps in knowledge of cancer risk factors

Lung cancer screening decision aid through tobacco quitlines improves informed decision-making

Study: liquid biopsy is an effective predictor of stage III melanoma relapse

First-ever single-cell analysis of uveal melanoma reported

Drugs & Targets

EMA accepts tucatinib application in HER2-positive breast cancer

EMA accepts application for belantamab mafodotin for multiple myeloma

European advisory group backs Pfizer's Rituxan biosimilar

FDA, FTC collaborate to deter anti-competitive practices involving biosimilars

NCI Trials

NCI Trials for Feb. 2020

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 50 | Issue 41 - November 01, 2024

Are drugs really driving the latest drop in lung cancer mortality?

ACS's Siegel: Large drop in lung cancer mortality likely driven by treatment, not just drugs

NCI's Penberthy: We may be seeing some impact of treatment in lung cancer mortality, but we need more data

American Cancer Society CEO Gary Reedy cedes day-to-day operations to chief operating officer

In Brief

Satish Gopal named director of the NCI Center for Global Health

Livestrong updates its mission—and unveils new logo

David Ann, Yilun Liu named deans at City of Hope graduate program

Krystyna Kowalczyk named CEO of Moffitt's immunotherapy CRO

Brandi Felser named executive director of Sarcoma Foundation of America

LUNGevity releases state-by-state Lung Cancer Scorecard

UPenn receives ACGT grant for CAR T-cell clinical trial in prostate cancer

Clinical Roundup

Survey finds gaps in knowledge of cancer risk factors

Lung cancer screening decision aid through tobacco quitlines improves informed decision-making

Study: liquid biopsy is an effective predictor of stage III melanoma relapse

First-ever single-cell analysis of uveal melanoma reported

Drugs & Targets

EMA accepts tucatinib application in HER2-positive breast cancer

EMA accepts application for belantamab mafodotin for multiple myeloma

European advisory group backs Pfizer's Rituxan biosimilar

FDA, FTC collaborate to deter anti-competitive practices involving biosimilars

NCI Trials

NCI Trials for Feb. 2020

Recent Issues

Renew today!

Subscriber content

Login